-
Tips for becoming a good boxer - November 6, 2020
-
7 expert tips for making your hens night a memorable one - November 6, 2020
-
5 reasons to host your Christmas party on a cruise boat - November 6, 2020
-
What to do when you’re charged with a crime - November 6, 2020
-
Should you get one or multiple dogs? Here’s all you need to know - November 3, 2020
-
A Guide: How to Build Your Very Own Magic Mirror - February 14, 2019
-
Our Top Inspirational Baseball Stars - November 24, 2018
-
Five Tech Tools That Will Help You Turn Your Blog into a Business - November 24, 2018
-
How to Indulge on Vacation without Expanding Your Waist - November 9, 2018
-
5 Strategies for Businesses to Appeal to Today’s Increasingly Mobile-Crazed Customers - November 9, 2018
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Large
ANI Pharmaceuticals, Inc. has dropped 0.13% during the last 3-month period. The company shares have rallied 73.12% in the past 52 Weeks. Celgene Corporation (CELG) has a weekly performance of – 0.570% and EPS growth this year of 42.30%.
Advertisement
Nabors Industries Ltd. (NBR) of the Basic Materials sector is down -0.52% trading at a volume of 284620 shares.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) rose 7.99% or 4.97 points on Monday and made its way into the gainers of the day.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded higher in the last at $63.41, gaining 2.03 points or 3.31%. The heightened volatility saw the trading volume jump to 178,124 shares. During yesterday’s rise and fall it had swelled to a high of $64.04 and plunged to a low of $61.81. The Israeli company, the largest generic company in the world, is widely expected to increase its $82-a-share offer. ANI Pharmaceuticals’ current market cap stands at $765.83 million. The total value of transaction was $997,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Advertisement
Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, “I am excited to add this group of approved products to our generic portfolio and to further leverage our manufacturing capabilities”. The shares has been rated as hold from 7 Wall Street Analysts. It manufactures oral solid dose products, as well as liquids and topicals, including narcotics. The Company has launched three products and has 11 products in development. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects, the Company’s pipeline or potential markets therefore, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates”, “will”, “expects”, “plans”, “potential”, “future”, “believes”, “intends”, “continue”, other words of similar meaning, derivations of such words and the use of future dates.